Completed
A Phase III Controlled, Double-Blind, Randomized, Multinational Study for the Preventative Therapy of Latent Tuberculosis in HIV-positive Individuals: Isoniazid (300 mg/day x 12 months ) vs. Rifabutin (300 mg/day x 3 months)
Learn MoreCompleted
A Randomized Trial of the Use of N-acetylcysteine for the Prevention of Sulphonamide Hypersensitivity Reactions When Used for the Prevention of Pneumocystis Carinii Pneumonia in Patients with HIV infection: Trial results
Learn MoreCompleted
Evaluation of SQ32,756 (BV ara U) Versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV Infected Patients
Learn MoreEnrolling
Association of vitamin D insufficiency with non-alcoholic fatty liver disease in HIV mono-infected patients
Learn MoreCompleted
Anemia Among HIV-infected Children Receiving Zidovudine: Identification of Markers of Erythropoietin Deficiency and Likelihood of Response to Exogenous Erythropoietin
Learn MoreCompleted
Rifabutin Therapy for the Prevention of MAC in Patients with AIDS
Learn MoreReporting
A pilot study of a novel, mRNA-based assay for the diagnosis of anal HPV infection HIV-positive MSM
Learn MoreReporting
Bone Antiresorptive Therapy with AntiRetroviral Initiation (BATARI) Pilot Trial
Learn MoreCompleted
Clinical Evaluation of Itraconazole vs. Ketoconazole in HIV+ Patients with Oropharyngeal and/or Oesophageal Candidiasis
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
